Alcon to acquire LumiThera to enhance dry AMD treatment
The acquisition includes LumiThera’s photo-bio-modulation (PBM) device, which leverages low-level light to treat early and intermediate dry age-related macular degeneration (AMD).

Educating the medical device manufacturing industry since 2002.
The acquisition includes LumiThera’s photo-bio-modulation (PBM) device, which leverages low-level light to treat early and intermediate dry age-related macular degeneration (AMD).
How long and complex healthcare supply chains perform depends on how effectively data is shared at all stages. Yet that data is often locked in silos, guarded by closed systems...
Simulating sustainability
Spinal cord regeneration
The pros of zwitterionic polymers
Better biosensing with nanomaterials